The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
A macrocyclic lactone that is rapamycin in which the hydroxy group attached to the cyclohexyl moiety has been converted into the corresponding 2-hydroxyethyl ether. It is an immunosuppressant and antineoplastic agent.
ABCB1A protein affects the stability of Everolimus bis(4-nitrophenyl)phosphate inhibits the reaction [ABCB1A protein affects the stability of Everolimus]; Everolimus inhibits the reaction [ABCB1A protein affects the metabolism of irinotecan] ABCB1 polymorphism affects the susceptibility to Everolimus
ABCB1B protein affects the stability of Everolimus bis(4-nitrophenyl)phosphate inhibits the reaction [ABCB1B protein affects the stability of Everolimus]; Everolimus inhibits the reaction [ABCB1B protein affects the metabolism of irinotecan]
ABCG2 protein affects the stability of Everolimus bis(4-nitrophenyl)phosphate inhibits the reaction [ABCG2 protein affects the stability of Everolimus]; Everolimus inhibits the reaction [ABCG2 protein affects the metabolism of irinotecan]
Everolimus results in increased phosphorylation of AKT1 protein Everolimus results in decreased phosphorylation of AKT1 protein Everolimus inhibits the reaction [Doxorubicin results in decreased phosphorylation of AKT1 protein]; MK 2206 inhibits the reaction [Everolimus inhibits the reaction [Doxorubicin results in decreased phosphorylation of AKT1 protein]]
Everolimus results in increased phosphorylation of AKT2 protein Everolimus inhibits the reaction [Doxorubicin results in decreased phosphorylation of AKT2 protein]; MK 2206 inhibits the reaction [Everolimus inhibits the reaction [Doxorubicin results in decreased phosphorylation of AKT2 protein]]
Everolimus inhibits the reaction [Doxorubicin results in decreased phosphorylation of AKT3 protein]; MK 2206 inhibits the reaction [Everolimus inhibits the reaction [Doxorubicin results in decreased phosphorylation of AKT3 protein]] Everolimus results in increased phosphorylation of AKT3 protein
Everolimus results in decreased expression of BIRC5 protein Everolimus promotes the reaction [platycodin D results in decreased expression of BIRC5 protein]; navitoclax promotes the reaction [Everolimus results in decreased expression of BIRC5 protein]; platycodin D promotes the reaction [Everolimus results in decreased expression of BIRC5 protein]
Everolimus results in increased expression of EGFR mRNA; Everolimus results in increased expression of EGFR protein platycodin D inhibits the reaction [Everolimus results in increased expression of EGFR protein]
Everolimus results in increased phosphorylation of EIF4E protein Everolimus inhibits the reaction [Estradiol results in decreased phosphorylation of EIF4E protein]
[letrozole co-treated with Everolimus] results in increased phosphorylation of and results in decreased activity of EIF4EBP1 protein; Everolimus inhibits the reaction [Estradiol results in increased phosphorylation of and results in decreased activity of EIF4EBP1 protein]; Everolimus promotes the reaction [platycodin D results in decreased phosphorylation of EIF4EBP1 protein]; Everolimus results in increased phosphorylation of and results in decreased activity of EIF4EBP1 protein; platycodin D promotes the reaction [Everolimus results in decreased phosphorylation of EIF4EBP1 protein]
platycodin D inhibits the reaction [Everolimus results in increased expression of IGF1R protein] Everolimus results in increased expression of IGF1R mRNA; Everolimus results in increased expression of IGF1R protein
Everolimus promotes the reaction [N-((1R,2S)-2-hydroxy-1-hydroxymethyl-2-(2-tridecyl-1-cyclopropenyl)ethyl)octanamide results in increased expression of and results in increased lipidation of MAP1LC3B protein]
[Everolimus co-treated with Y 27632] inhibits the reaction [4-cresol results in increased phosphorylation of MTOR protein]; [Letrozole co-treated with Everolimus] inhibits the reaction [Androstenedione affects the activity of MTOR protein]; Everolimus inhibits the reaction [4-cresol results in increased phosphorylation of MTOR protein]; Everolimus inhibits the reaction [Androstenedione affects the activity of MTOR protein]; Everolimus inhibits the reaction [Estradiol affects the activity of MTOR protein]; Everolimus inhibits the reaction [MTOR results in decreased susceptibility to Trabectedin] Everolimus results in decreased activity of MTOR; Everolimus results in decreased activity of MTOR protein Everolimus inhibits the reaction [rhodioloside inhibits the reaction [[cobaltous chloride co-treated with NGF protein] results in decreased phosphorylation of MTOR protein]] Everolimus results in decreased phosphorylation of MTOR protein
[MYC protein results in decreased susceptibility to Everolimus] promotes the reaction [BRD4 protein binds to MYC gene] Everolimus results in increased expression of MYC protein
Everolimus inhibits the reaction [rhodioloside inhibits the reaction [[cobaltous chloride co-treated with NGF protein] results in decreased phosphorylation of MTOR protein]]; Everolimus inhibits the reaction [rhodioloside inhibits the reaction [[cobaltous chloride co-treated with NGF protein] results in decreased phosphorylation of RPS6KB1 protein]]
Aspirin inhibits the reaction [Everolimus results in decreased expression of NOS3 protein]; cilostazol inhibits the reaction [Everolimus results in decreased expression of NOS3 protein]
[letrozole co-treated with Everolimus] results in decreased phosphorylation of and affects the activity of RB1 protein; Everolimus results in decreased phosphorylation of and affects the activity of RB1 protein Everolimus results in decreased phosphorylation of RB1 protein
Everolimus results in decreased expression of RHOA protein [Everolimus co-treated with Y 27632] inhibits the reaction [4-cresol results in increased expression of RHOA protein]
[letrozole co-treated with Everolimus] results in decreased phosphorylation of RPS6 protein; Everolimus inhibits the reaction [Estradiol results in increased phosphorylation of RPS6 protein] Everolimus results in decreased phosphorylation of RPS6 protein
Everolimus inhibits the reaction [rhodioloside inhibits the reaction [[cobaltous chloride co-treated with NGF protein] results in decreased phosphorylation of RPS6KB1 protein]] Everolimus inhibits the reaction [Estradiol results in increased phosphorylation of RPS6KB1 protein]; Everolimus inhibits the reaction [TNF protein results in increased phosphorylation of RPS6KB1 protein]
Aspirin inhibits the reaction [Everolimus results in decreased expression of SIRT1 protein]; cilostazol inhibits the reaction [Everolimus results in decreased expression of SIRT1 protein]
Everolimus inhibits the reaction [TNF protein results in increased phosphorylation of RPS6KB1 protein]; Everolimus promotes the reaction [TNF protein results in increased expression of F3 protein]